HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Zivin, J. A. Search for Related Content PubMed PubMed Citation Articles by Zivin, J. A.

Cyproheptadine reduces or prevents ischemic central nervous system damage

Department of Neurology, University of Massachusetts Medical Center, Worcester, MA.

Several drugs that inhibit the effects of serotonin may reduce or prevent experimental CNS ischemic damage, but these drugs are not approved for human use in the United States. Administration of cyproheptadine (which is available for clinical use) 15 minutes before or 5 minutes after the onset increased the duration of experimental rabbit spinal cord ischemia required to produce irreversible paraplegia. Drugs thought to be serotonin agonists did not aggravate the damage, but bufotenin reversed protective effects of cyproheptadine. The results suggest that serotonin antagonists reduce ischemic CNS damage; cyproheptadine may be a potential treatment for ischemic stroke.

Address correspondence and reprint requests to Dr. Zivin, Department of Neurology, University of Massachusetts Medical Center, 55 Lake Avenue, North, Worcester, MA 01605.

Supported by grants from the National Institutes of Health (NS 00456 and NS 15827).

Accepted for publication August 16, 1984.